معرفی
Professor Chris Bunce is a faculty member at the University of Birmingham's School of Biosciences, holding the position of Professor of Translational Cancer Biology and Head of Research. His work focuses on developing novel therapies for leukaemias and lymphomas, emphasizing drug redeployment using off-patent drugs to ensure affordability and accessibility globally. Bunce's research integrates molecular mechanisms, such as apoptosis and differentiation pathways, to design targeted treatments. He leads a translational research group and has pioneered clinical trials for drug combinations like medroxyprogesterone acetate and bezafibrate, notably in AML and Malawian Burkitt lymphoma studies.
Education: BSc and PhD in Immunology from the University of Birmingham. Career highlights include the 1997 Leukaemia Research Fund Bennett Senior Fellowship and roles as a Senior Lecturer and Reader in Experimental Haematological Oncology. Bunce is also the founder of StemTrax, a spin-out company advancing stem cell therapies using recombinant Nm23H1 protein.
Research interests include enzyme inhibitors (e.g., AKR1C3), metabolic pathways in cancer cells, and the exploitation of existing drugs for new applications. He actively reviews for journals like Blood and Cancer Research, and sits on the steering committee of the Birmingham University Stem Cell Centre. Bunce’s contributions bridge basic science and clinical application, aiming to improve outcomes for older cancer patients through less toxic therapies.
Awards: Leukaemia Research Fund Bennett Senior Fellowship (1997). Collaborations extend to clinical trials in low-resource settings, underscoring his commitment to equitable healthcare.
